Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 312

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 312
---
 ZTlido. The two Apotex entities were dismissed from the litigation without prejudice, as they no longer had an interest in the generic product that Aveva seeks to market. Before trial, Aveva dropped its challenge to the validity and
enforceability of the Company’s patents. Trial in the ZTlido Patent Litigation was held from July 8, 2024 to July 11, 2024. Final post-trial briefing was submitted by the parties on July 25, 2024, and the case was submitted to
the U.S. District Court for the Southern District of Florida. On August 26, 2024, that court issued a decision finding that Aveva’s product does not infringe our ZTlido Patents. We are appealing that decision to the U.S. Court of Appeals
for the Federal Circuit, and we filed a Notice of Appeal with the U.S. District Court for the Southern District of Florida on September 25, 2024.

Our Corporate History

Legacy Scilex was
incorporated in Delaware in February 2019 for the purpose of effecting a corporate reorganization. On March 18, 2019, Legacy Scilex entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of
capital stock of Scilex Pharma pursuant to which Legacy Scilex acquired 100% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of Legacy Scilex Common Stock (such transaction, the “Contribution”). Pursuant
to the Contribution and Loan Agreement, Sorrento provided Legacy Scilex with a loan with an initial principal amount of $16.5 million in the form of a note payable, which loan was used to fund the acquisition of Semnur. Concurrently therewith,
Legacy Scilex entered into the Semnur Acquisition Agreement with Semnur, Sigma Merger Sub, Inc., Legacy Scilex’s prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur equity, and Sorrento, for
limited purposes. Pursuant to the Semnur Acquisition Agreement, Sigma Merger Sub, Inc. merged with and into Semnur, with Semnur surviving the Semnur Acquisition as Legacy Scilex’s wholly owned subsidiary. As a result of the Contribution and the
Semnur Acquisition, Scilex Pharma and Semnur became Legacy Scilex